Premium Nahrungsergänzungsmittel | artgerecht

Major Basic Protein – Function and Clinical Role

Major Basic Protein (MBP) is a cytotoxic protein found in eosinophil granules, playing a key role in allergic reactions, parasite defense, and eosinophilic inflammation.

Regular tips about health Regular tips about health

Things worth knowing about "Major Basic Protein"

Major Basic Protein (MBP) is a cytotoxic protein found in eosinophil granules, playing a key role in allergic reactions, parasite defense, and eosinophilic inflammation.

What is Major Basic Protein?

Major Basic Protein (MBP) is a highly basic, cytotoxic protein stored predominantly in the crystalline core of eosinophil granules. It constitutes approximately 50% of the total protein content of these granules, making it the most abundant protein in eosinophilic granulocytes. Its name reflects its biochemical nature: it is strongly basic (positively charged) and structurally dominant within the granules of eosinophils.

MBP belongs to the C-type lectin family and carries a high density of positive charges, enabling it to interact with and disrupt negatively charged structures on the surfaces of cells and pathogens.

Biological Function and Mechanism of Action

Major Basic Protein fulfills several important immunological roles in the human body:

Parasite defense: MBP can destroy the membranes of parasites, particularly helminths (worm parasites), by interacting electrostatically with their negatively charged surfaces and destabilizing their cell membranes.
Antimicrobial activity: MBP exerts toxic effects on various bacteria, viruses, and fungi, contributing to innate immune defense.
Immune cell activation: MBP can activate mast cells and basophils, triggering the release of histamine and other inflammatory mediators.
Tissue damage in inflammation: When released in an uncontrolled manner, MBP can damage host tissues, which is particularly relevant in allergic and chronic inflammatory conditions.

Clinical Relevance and Associated Conditions

Allergic and Atopic Diseases

In conditions such as allergic asthma, atopic dermatitis, and allergic rhinitis, increased eosinophil activation leads to excessive MBP release. The released protein damages airway mucosa, promotes inflammatory reactions, and contributes to bronchial hyperreactivity. Elevated MBP concentrations can be detected in the sputum and tissue of patients with asthma.

Eosinophilic Disorders

In conditions such as hypereosinophilic syndrome or eosinophilic esophagitis, excessive degranulation of eosinophils and the associated MBP release cause tissue damage in multiple organs, including the heart, lungs, nervous system, and gastrointestinal tract.

Parasitic Infections

During infections with helminths such as Toxocara or Schistosoma, MBP is specifically deployed to kill the parasites. This explains the characteristic elevation of eosinophil counts (eosinophilia) seen in blood tests during worm infections.

Pregnancy

Placental cells also produce a form of MBP, known as MBP-2 or placental MBP. Its function during pregnancy is not yet fully understood, but roles in immune tolerance and placental development have been proposed.

Diagnostic Relevance

Measurement of Major Basic Protein in blood, sputum, or tissue samples can be used diagnostically to assess the extent of eosinophilic inflammation. Elevated MBP levels indicate active eosinophilic inflammatory activity and are relevant in the following clinical contexts:

Assessment of allergic asthma severity
Diagnosis and monitoring of eosinophilic esophagitis
Detection of parasitic infections
Monitoring of patients with hypereosinophilic syndrome

Therapeutic Approaches

Because MBP plays a central role in eosinophilic inflammation, several modern treatment strategies aim to reduce eosinophil activity and thereby limit MBP release:

Corticosteroids: Inhibit eosinophil activation and degranulation, thereby reducing MBP release.
Biologics: Monoclonal antibodies such as mepolizumab, reslizumab, and benralizumab target interleukin-5 (IL-5) or its receptor, specifically reducing eosinophil numbers and activation.
Antiparasitic therapy: In parasitic infections, treatment targets the causative organism, which secondarily normalizes eosinophil counts and MBP levels.

References

Gleich, G.J. et al. - The major basic protein of eosinophil granules: its role in immunity and disease. In: Journal of Allergy and Clinical Immunology, 1986.
Rothenberg, M.E. & Hogan, S.P. - The eosinophil. In: Annual Review of Immunology, 2006; 24: 147-174.
World Allergy Organization (WAO) - Eosinophilic Disorders: Mechanisms and Management. WAO White Book on Allergy, 2013.

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.